Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors

Gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) represent the most common subtype of NETs. The incidence of all NETs, and specifically GEP NETs, has risen exponentially over the last three decades. Only within the past several years have these tumors been appropriately classified, allowing...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Satya, Dasari, Arvind
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141991/
https://www.ncbi.nlm.nih.gov/pubmed/34093744
http://dx.doi.org/10.1177/17588359211018047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141991/
https://www.ncbi.nlm.nih.gov/pubmed/34093744
http://dx.doi.org/10.1177/17588359211018047

Ejemplares similares